> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Regulatory Review Period for Oxervate
- URL: https://www.fdaweb.com/regulatory-review-period-for-oxervate/
- Published: 2020-08-21T12:00:00.000Z
- Updated: 2026-09-14T16:26:02.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5147485

*Federal Register* notice: FDA has determined for patent extension purposes the regulatory review period for Dompe Farmaceutici’s Oxervate (cenegermin-bkbj), indicated for treating neurotrophic keratitis. The regulatory review period is 1,484 days, which includes 1,240 days during the testing phase and 244 days during the approval phase. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2020-08-20/pdf/2020-18239.pdf?ref=fdaweb.com).